About this Journal Submit a Manuscript Table of Contents 
Prostate Cancer
Volume 2012 (2012), Article ID 524206, 4 pages
doi:10.1155/2012/524206
Research Article

Vitamin D Levels in Subjects with Prostate Cancer Compared to Age-Matched Controls

Subhashini Yaturu,1 Sonya Zdunek,2 and Barbara Youngberg3

1Department of Endocrinology, Stratton VA Medical Center, Albany, NY 12208, USA
2IT Department, Stratton VA Medical Center, Albany, NY 12208, USA
3Department of Research, Stratton VA Medical Center, Albany, NY 12208, USA

Received 19 October 2012; Revised 25 November 2012; Accepted 27 November 2012

Academic Editor: Manfred P. Wirth

Copyright © 2012 Subhashini Yaturu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.cdc.gov/cancer/prostate/index.htm.
  2. M. F. Holick, “Medical progress: vitamin D deficiency,” New England Journal of Medicine, vol. 357, no. 3, pp. 266–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Nair and A. Maseeh, “Vitamin D: the “sunshine” vitamin,” Journal of Pharmacology and Pharmacotherapeutics, vol. 3, no. 2, pp. 118–126, 2012.
  4. M. L. Melamed, E. D. Michos, W. Post, and B. Astor, “25-hydroxyvitamin D levels and the risk of mortality in the general population,” Archives of Internal Medicine, vol. 168, no. 15, pp. 1629–1637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Gandini, M. Boniol, J. Haukka et al., “Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma,” International Journal of Cancer, vol. 128, no. 6, pp. 1414–1424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Yin, E. Raum, U. Haug, V. Arndt, and H. Brenner, “Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk,” Cancer Epidemiology, vol. 33, no. 6, pp. 435–445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Gilbert, R. M. Martin, R. Beynon et al., “Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis,” Cancer Causes and Control, vol. 22, no. 3, pp. 319–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Raimondi, H. Johansson, P. Maisonneuve, and S. Gandini, “Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk,” Carcinogenesis, vol. 30, no. 7, pp. 1170–1180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Ahn, U. Peters, D. Albanes et al., “Serum vitamin D concentration and prostate cancer risk: a nested case-control study,” Journal of the National Cancer Institute, vol. 100, no. 11, pp. 796–804, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Tseng, V. Giri, D. Watkins-Bruner, and E. Giovannucci, “Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer,” Cancer Causes and Control, vol. 20, no. 10, pp. 1947–1954, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Brändstedt, M. Almquist, J. Manjer, and J. Malm, “Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study,” Cancer Causes and Control, vol. 23, no. 8, pp. 1377–1385, 2012. View at Publisher · View at Google Scholar
  12. A. Cranney, T. Horsley, S. O'Donnell et al., “Effectiveness and safety of vitamin D in relation to bone health,” Evidence Report/Technology Assessment, no. 158, pp. 1–235, 2007.
  13. R. P. Heaney, L. A. G. Armas, J. R. Shary, N. H. Bell, N. Binkley, and B. W. Hollis, “25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions,” American Journal of Clinical Nutrition, vol. 87, no. 6, pp. 1738–1742, 2008. View at Scopus
  14. M. W. J. Davie, D. E. M. Lawson, and C. Emberson, “Vitamin D from skin: contribution to vitamin D status compared with oral vitamin D in normal and anticonvulsant-treated subjects,” Clinical Science, vol. 63, no. 5, pp. 461–472, 1982. View at Scopus
  15. A. Timpini, L. Pini, C. Tantucci, S. Cossi, and V. Grassi, “Vitamin D and health status in elderly,” Internal and Emergency Medicine, vol. 6, no. 1, pp. 11–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Jungert, H. J. Roth, and M. Neuhauser-Berthold, “Serum 25-hydroxyvitamin D3 and body composition in an elderly cohort from Germany: a cross-sectional study,” Nutrition & Metabolism, vol. 9, article 42, 2012. View at Publisher · View at Google Scholar
  17. C. Halthur, A. L. V. Johansson, M. Almquist et al., “Serum calcium and the risk of prostate cancer,” Cancer Causes and Control, vol. 20, no. 7, pp. 1205–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Giovannucci, D. M. Harlan, M. C. Archer et al., “Diabetes and cancer: a consensus report,” Diabetes Care, vol. 33, no. 7, pp. 1674–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. R. Shastri and S. Yaturu, “Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer,” Prostate Cancer, vol. 2011, Article ID 391576, 9 pages, 2011. View at Publisher · View at Google Scholar
  20. I. H. Derweesh, C. J. DiBlasio, M. C. Kincade et al., “Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer,” BJU International, vol. 100, no. 5, pp. 1060–1065, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. H. S. Kim, J. C. Presti, W. J. Aronson et al., “Glycemic control and prostate cancer progression: results from the SEARCH database,” Prostate, vol. 70, no. 14, pp. 1540–1546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. K. Hong, S. T. Lee, S. S. Kim et al., “Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer,” Prostate, vol. 69, no. 8, pp. 820–826, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Datta and G. G. Schwartz, “Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer: a critical review,” Oncologist, vol. 17, no. 9, pp. 1171–1179, 2012. View at Publisher · View at Google Scholar
  24. S. Yaturu, S. DjeDjos, G. Alferos, and C. Deprisco, “Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy,” Prostate Cancer and Prostatic Diseases, vol. 9, no. 1, pp. 35–38, 2006. View at Publisher · View at Google Scholar · View at Scopus